EUVIMEDSkopri EUVIMED
VergleichsstudieOpen access · CC BY-NC-ND 4.0

Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study

Jiafang Yao, Qiyin Sun, Dan Liu, Junling Lin, WenJuan Wang

BMC Cardiovascular Disorders · 2026-05-16 · 26 (1)

DOI: 10.1186/s12872-026-05931-5 ↗

At a glance

Vergleichsstudie in BMC Cardiovascular Disorders, published online on 2026-05-16. Written by Jiafang Yao and 4 co-authors. Institution: Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000,…. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Cholesterol, LDL, PCSK9 Inhibitors, Anticholesteremic Agents. 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ebda abstract disponibbli.

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedCholesterol, LDLPCSK9 InhibitorsAnticholesteremic AgentsAntibodies, MonoclonalDyslipidemiasSerine Proteinase InhibitorsHumansFemaleTreatment OutcomeRetrospective StudiesMaleBiomarkersTime FactorsMiddle AgedApolipoprotein B-100Proprotein Convertase 9AgedAdult

Author keywords

AlirocumabApoBEvolocumabInclisiranLDL-CPCSK9 inhibitorReal-world study

Substances

Antibodies, Monoclonal, HumanizedalirocumabevolocumabCholesterol, LDLBiomarkersPCSK9 InhibitorsAnticholesteremic AgentsPCSK9 protein, humanAPOB protein, humanApolipoprotein B-100

Authors and institutions

  • Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000, China.
  • Department of Nephrology, Huzhou Central, Hospital, Huzhou, China.
  • Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000, China. wwjyy0712@126.com.

Funding

  • Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project

Cite

APA

Yao, J., Sun, Q., Liu, D., Lin, J., & Wang, W. (2026). Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. BMC Cardiovascular Disorders, 26(1). https://doi.org/10.1186/s12872-026-05931-5

Vancouver

Yao J, Sun Q, Liu D, Lin J, Wang W. Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. BMC Cardiovascular Disorders. 2026;26(1). doi:10.1186/s12872-026-05931-5

BibTeX
@article{Yao2026,
  author = {Yao, Jiafang and Sun, Qiyin and Liu, Dan and Lin, Junling and Wang, WenJuan},
  title = {Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study},
  journal = {BMC Cardiovascular Disorders},
  year = {2026},
  volume = {26},
  number = {1},
  doi = {10.1186/s12872-026-05931-5}
}
Start for free →